The Meme ETF is back — just in time to test whether we’ve learned anything since 2021.

Roundhill’s MEME fund relaunched today with a fresh crop of volatile darlings like Opendoor $OPEN ( ▼ 3.18% ), Plug Power $PLUG ( ▲ 0.27% ), and QuantumScape $QS ( ▲ 5.02% ).

Last time it debuted, the Nasdaq topped out within weeks.

Finally, read to the end for the entire investor psyche in a single meme…

— Brooks & Cas

Automation’s the future, but 71% of execs say upfront costs prevent its adoption. That’s why Miso Robotics’ new $25M hardware financing facility for customers turned heads. Miso’s AI-powered kitchen robots have logged 200k+ hours for brands like White Castle. With this $25M line and partnerships with NVIDIA, Amazon, it’s unlocking quick, flexible adoption of cutting-edge automation. Invest before Miso’s bonus shares change on 10/9.

_{This is a paid advertisement for Miso Robotics’ Regulation A offering. Please read the offering circular at invest.misorobotics.com.}

$RKLB ( ▲ 3.89% ) Rocket Lab's Shares Lift on New Multi-Mission Satellite Launch Deals (Investopedia)

$CRWV ( ▼ 0.87% ) CoreWeave stock rallies as company introduces new AI tools for developers (CNBC)

$JOBY ( ▼ 1.7% ) Joby Tumbles On $513 Million Stock Offering After Air Taxi Demos (IBD)

$VSAT ( ▼ 2.02% ) Viasat secures contract for U.S. Space Force satellite program (Investing.com)

$CFLT ( ▲ 2.58% ) Data streaming software maker Confluent explores sale, sources say (Reuters)

CNBC: Fed minutes showed officials favored rate cuts this year, with most expecting two more as labor market weakness persisted.

Bloomberg: Elon Musk’s xAI expanded its funding round to $20B with backing from Nvidia $NVDA ( ▲ 2.76% ), using a special vehicle to finance Colossus 2.

CNN: Domino’s $DPZ ( ▼ 0.6% ) unveiled its first rebrand in 13 years with a bolder logo, new uniforms, and a Shaboozey-performed jingle.

QZ: KFC $YUM ( ▼ 0.58% ) brought back its Original Honey BBQ chicken and cut sandwich prices to $3.99 as nostalgia-driven menu revivals boost sales.

Reuters: GM $GM ( ▼ 0.12% ) scrapped its plan to extend $7,500 EV lease tax credits past September after the federal subsidy expired.

Guggenheim $GOF ( ▼ 0.17% ) says shares of CG Oncology $CGON ( ▲ 6.73% ) could more than double from here. The only question left for investors is, “Who…?”

The firm initiated coverage of the little-known bladder cancer treatment biotech with a Buy rating and a $90 price target, implying around 121% upside from the stock’s close today. Analyst Brad Canino highlighted CG Oncology’s strong footing in a growing segment with substantial pricing power and long treatment durations.

He described the company’s lead therapy, cretostimogene, as “best-in-class” in efficacy, durability, and safety, noting that it will enter FDA review next year.

Cretostimogene is an oncolytic immunotherapy designed to stimulate the immune system to target bladder cancer cells. Canino said the treatment’s profile is particularly well-suited to non-muscle invasive bladder cancer (NMIBC) patients, who seek to avoid invasive surgeries such as cystectomy.

Equally important, Canino noted, is that NMIBC patients tend to have a non-lethal form of cancer, heightening the demand for drugs with pristine safety records — an area where cretostimogene could potentially stand out.

Guggenheim believes that the combination could help CG Oncology carve out a leading position in a field that has seen limited innovation over the past decade.

Guggenheim also pointed to what it called a “potentially attractive catalyst path,” citing a string of data releases and regulatory updates expected over the next two years. Those milestones could help maintain investor attention on the name as it moves closer to commercialization.

Wall Street appears to agree: all 12 analysts covering CG Oncology currently rate it a Buy or Strong Buy, according to LSEG data.

For investors willing to stomach biotech volatility, analysts say the company’s mix of strong science, a clear market opportunity, and multiple near-term catalysts could make it one of the most compelling small-cap healthcare stories heading into 2026.

If you’ve got $5,000+ in savings, stop settling for low interest.

Find high-yield accounts that pay you more, fast.

Tap here or below to compare rates and boost your savings today.

QZ: Flight delays and cancellations mounted as unpaid air traffic controllers called in sick during the second week of the US government shutdown.

CNBC: What’s more, the FAA warned flight delays could worsen amid the shutdown due to an air traffic controller shortage already disrupting major airports.

Axios: Retailers and drone firms criticized a proposed FAA rule requiring TSA-style screening for delivery staff, warning it would cripple drone operations.

AP: IMF chief Kristalina Georgieva said global growth should hold at 3% despite Trump’s tariffs but warned that uncertainty is “the new normal”.

CNN: Denmark announced plans to ban social media for children under 15, citing rising youth anxiety and declining social interaction.

Weathering the liquidity storm.

It’s been that kind of week: bond yields up, stocks sideways, and the internet once again debating whether gold and Bitcoin are “real” hedges.

Through it all, our amphibious friend remains unmoved.

Are you bullish or bearish on Astera Labs $ALAB ( ▲ 1.66% ) over the next 12 months?

▇▇▇▇▇▇ 🐂 Bullish

▇▇▇▇▇▇ 🐻 Bearish

And, in response, you said: